Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Researchers found that ActiveLife Scientific,s ... with bone fragility fracture when today,s standard bone ... are at risk of fracture for reasons that ... test, the DEXA bone density scan.  Study results ... and Mineral Research Annual Conference (ASBMR) in ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... NC (PRWEB) September 15, 2014 ... developed deep imaging OCT system for the optical device ... The EnvisuTM S4410 SDOCT for Contact Lens ... for standard and high complexity contact lens, IOL structures, ... imaging of a complete contact lens immersed in a ...
Breaking Biology Technology:ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
... , , , ... ) announced that it will be hosting a conference call to discuss today,s ... begin at 8:30 a.m. Eastern Time (ET)/5:30 a.m. Pacific Time (PT). , ... accessed through a link that is posted on the home page of Nektar,s ...
... ... firms have to follow a rigorous documentation process to comply with a ... corporate agreements these firms are faced with the daunting task of sharing ... affordable unlimited use facility to share thousands of confidential documents securely and ...
... question, researchers with the U.S. Department of Energy,s ... that the selective placement of strain can alter ... correlated electron materials. This unique class of materials ... display properties such as colossal magnetoresistance and high-temperature ...
Cached Biology Technology:Nektar Therapeutics to Host Conference Call to Discuss Today's Announcement of a New Partnership for NKTR-118 and NKTR-119 2Life Science Firms are Turning to Firmex to do Deals Online 2Life Science Firms are Turning to Firmex to do Deals Online 3Strain on nanocrystals could yield colossal results 2Strain on nanocrystals could yield colossal results 3
(Date:9/15/2014)... gut microbes influence processes from digestion to disease resistance. ... biodiverse terrestrial ecosystems on the planet, more is known ... tropics. Smithsonian scientists and colleagues working on Panama,s Barro ... single tree were home to more than 400 different ... species contained more than 7,000 different kinds. , Bacteria ...
(Date:9/15/2014)... a morphine regimen can result in better pain control ... the dosage of the opioid needed to be effective, ... University. , The result could bring significant relief to ... felt in the arms and legs and associated with ... need for better treatments for neuropathic pain," said Fletcher ...
(Date:9/15/2014)... print issue of the journal Science comes ... Mexico, Montana and even the Netherlands, thanks to the ... the norm in these connected times. Yes, the research ... innovations in biology, medicine, biotechnology and agriculture. It could ... with that one, that one knew another one, and ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2Collaboration drives achievement in protein structure research 2
... early bird rates for the premier bone meeting in 2012. ... 21-24, 2012 will be held in in the magnificent city ... register by December 9, 2011 at http://www.iof-ecceo12.org ... key thought leaders... Plenary lectures:, The conundrum ...
... now possible to use dental X-rays to predict who is ... at the Sahlgrenska Academy reported in the journal Nature ... the University of Gothenburg,s Sahlgrenska Academy and Region Vstra Gtaland ... in the lower jaw is linked to a greater chance ...
... and more solar modules are appearing on rooftops, and ... into the grid. Multi-junction solar cells are particularly efficient ... to 43 percent - twice the level of conventional ... consist of several semi-conductor layers that combine to transform ...
Cached Biology News:Register now for the European Congress on Osteoporosis & Osteoarthritis in Bordeaux 2Dental X-rays can predict fractures 2Fraunhofer researchers receive the Franco-German Business Award 2011 2
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
... RNase Inhibitor (patent pending) is a protein ... binds and inhibits the most common and ... 1 and T1. SUPERaseIn can be used ... be problematic. It is ideal for in ...
... Recombinant Ribonuclease Inhibitor is a ... ribonucleases such as RNase A. ... Recombinant Ribonuclease Inhibitor is an ... weight ~52 kDa. RNaseOUT inhibits ...
Biology Products: